Link to SME partners:
AlbaJuna Therapeutic SL
Leaf Expression Systems Ltd
Link to Academic and Public
research organization partners:
Hospital Medical School
The University of Rouen
John Innes Centre
University of the Arts London
VTT Technical Research Centre of Finland
Founded in 2011, Root Lines Technology, now SamaBriva, is a French biotechnology company specialized in the development of innovative biotherapeutics to treat Lysosomal Storage Disorders (LSD), a group of rare genetic diseases.
Samabriva harnesses two innovative technology platforms that can be used independently:
- Its NanoBrivaTM platform that allowsfor the design of novel, proprietary recombinant therapeutic enzymes engineered to confer superior tissue penetrance in hard-to-target organs, such as the brain, as well as slow-release pharmacokinetics;
- Its historical RhizoBrivaTM platform, a state-of-the-art highly versatile bioreactor-confined plant-based bioprocessing technology allowing the safe and cost-effective production of complex, functionally active molecules.
RhizoBrivaTM demonstrated competitive stability and reproducibility in its production of complex proteins, secreted in a simple, animal, hormone and virus-free culture medium, thus enabling a straightforward purification step. Samabriva’s team demonstrated the high homogeneity of the complex proteins glycosylation profiles using its innovative platform. The latter displays a GMP-like process with a regulatory pathway well validated through a scientific advice from the French regulatory agency. Using its innovative processes, SamaBriva has demonstrated its ability to produce, from hairy roots, recombinant proteins with the same activity as the equivalent drug produced using classical mammalian cells.
RhizoBrivaTM capitalizes on the research done by a world class academic team through the acquisition of worldwide and exclusive licensing of patents underlying this approach based on the development of a production system of recombinant proteins from plant ‘hairy roots’.
With several years of service delivery and collaborations SamaBriva has validated this technology with respect to market expectations and achieved the quality levels required for the development of proprietary human recombinant proteins for therapeutic use.
Marina GUILLET, Ph.D., CEO of SamaBriva and Workpackage 3 Leader: >15 years hands-on experience in the biotechnology business: from the creation of companies to various management positions (including scientific management as CSO and management of an ISO17025 accredited laboratory).
Florian Cardon, Eng. MBA, Head of Operations: strong experience in the development of recombinant proteins using various systems among which an alternative plant-based system of expression and development of bioprocesses.
Camille Lemasson, Ph.D, R&D Project Manager: PhD degree in Process Engineering from the University of Nantes in France and specialized in plant based bioprocesses. In charge of the plant culture unit.